Dupilumab Decreases Blood Biomarkers in Adolescents With Moderate-to-Severe Atopic Dermatitis: Data From a Phase 3 Trial (LIBERTY AD ADOL). J of Skin. 2020;4(5):s49. doi:10.25251/skin.4.supp.48